Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,203 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Phase I trial of anti-CS1 monoclonal antibody elotuzumab in combination with bortezomib in the treatment of relapsed/refractory multiple myeloma.
Jakubowiak AJ, Benson DM, Bensinger W, Siegel DS, Zimmerman TM, Mohrbacher A, Richardson PG, Afar DE, Singhal AK, Anderson KC. Jakubowiak AJ, et al. Among authors: anderson kc. J Clin Oncol. 2012 Jun 1;30(16):1960-5. doi: 10.1200/JCO.2011.37.7069. Epub 2012 Jan 30. J Clin Oncol. 2012. PMID: 22291084 Free PMC article. Clinical Trial.
NF-kappa B as a therapeutic target in multiple myeloma.
Hideshima T, Chauhan D, Richardson P, Mitsiades C, Mitsiades N, Hayashi T, Munshi N, Dang L, Castro A, Palombella V, Adams J, Anderson KC. Hideshima T, et al. Among authors: anderson kc. J Biol Chem. 2002 May 10;277(19):16639-47. doi: 10.1074/jbc.M200360200. Epub 2002 Feb 28. J Biol Chem. 2002. PMID: 11872748 Free article.
2-Methoxyestradiol overcomes drug resistance in multiple myeloma cells.
Chauhan D, Catley L, Hideshima T, Li G, Leblanc R, Gupta D, Sattler M, Richardson P, Schlossman RL, Podar K, Weller E, Munshi N, Anderson KC. Chauhan D, et al. Among authors: anderson kc. Blood. 2002 Sep 15;100(6):2187-94. doi: 10.1182/blood-2002-02-0376. Blood. 2002. PMID: 12200384 Free article.
Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma.
Richardson PG, Schlossman RL, Weller E, Hideshima T, Mitsiades C, Davies F, LeBlanc R, Catley LP, Doss D, Kelly K, McKenney M, Mechlowicz J, Freeman A, Deocampo R, Rich R, Ryoo JJ, Chauhan D, Balinski K, Zeldis J, Anderson KC. Richardson PG, et al. Among authors: anderson kc. Blood. 2002 Nov 1;100(9):3063-7. doi: 10.1182/blood-2002-03-0996. Blood. 2002. PMID: 12384400 Free article. Clinical Trial.
Molecular sequelae of proteasome inhibition in human multiple myeloma cells.
Mitsiades N, Mitsiades CS, Poulaki V, Chauhan D, Fanourakis G, Gu X, Bailey C, Joseph M, Libermann TA, Treon SP, Munshi NC, Richardson PG, Hideshima T, Anderson KC. Mitsiades N, et al. Among authors: anderson kc. Proc Natl Acad Sci U S A. 2002 Oct 29;99(22):14374-9. doi: 10.1073/pnas.202445099. Epub 2002 Oct 21. Proc Natl Acad Sci U S A. 2002. PMID: 12391322 Free PMC article.
Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341.
Hideshima T, Mitsiades C, Akiyama M, Hayashi T, Chauhan D, Richardson P, Schlossman R, Podar K, Munshi NC, Mitsiades N, Anderson KC. Hideshima T, et al. Among authors: anderson kc. Blood. 2003 Feb 15;101(4):1530-4. doi: 10.1182/blood-2002-08-2543. Epub 2002 Sep 26. Blood. 2003. PMID: 12393500 Free article.
1,203 results